Targeting Breast Cancer Metabolism: A Metabolic Control Analysis Approach
Manchester Centre for Integrative Systems Biology, Manchester Institute of Biotechnology, The University of Manchester, United Kingdom
- *Corresponding Author:
- Ettore Murabito
Manchester Centre for Integrative Systems Biology
Manchester Institute of Biotechnology
The University of Manchester, United Kingdom
Tel: +44 306 5146
E-mail: [email protected]
Received date: July 05, 2013; Accepted date: August 19, 2013; Published date: August 22, 2013
Citation: Murabito E (2013) Targeting Breast Cancer Metabolism: A Metabolic Control Analysis Approach. Curr Synthetic Sys Biol 1:104. doi:10.4172/2332-0737.1000104
Copyright: © 2013 Murabito E. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In many diseases, such as cancer, cells show a specific metabolic shift from their normal physiological state. The differences between the normal and the altered metabolic phenotypes may be exploited to identify points of fragility characterising the disease, and hence to specifically target altered cells. The application of Metabolic Control Analysis (MCA) has been proposed as a possible way to identify such points of fragility at the metabolic level. Here we use an MCA approach to assess the suitability of different enzymes as molecular targets for drugs designed to attack breast cancer. We base our study on experimental data characterising the metabolic features of breast cancer, and make use, where possible, of actual kinetic equations in the attempt to provide the most realistic description of the system under study. Unknown metabolic and kinetic quantities are sampled randomly, providing us with a probabilistic assessment of the control profile of the system in the two metabolic phenotypes. The suitability of the different enzymes as molecular targets is subsequently assessed with respect to criteria of both high efficacy and low toxicity.